Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15690266 | 0.80 | PDE10A (0.35) | TGFBR1DYRK1APDE10ACYP1A2POLB | |
| SCHEMBL15261493 | 0.80 | DYRK1A (0.40) | TGFBR1DYRK1APDE10ACYP1A2POLB | |
| SCHEMBL15715209 | 0.80 | TGFBR1 (0.45) | TGFBR1DYRK1ASCN5A | |
| SCHEMBL17132597 | 0.77 | CYP1A2 (0.33) | TGFBR1DYRK1APDE10ACYP1A2POLB | |
| SCHEMBL24113587 | 0.76 | PDE10A (0.42) | DYRK1APDE10APOLB | |
| SCHEMBL10591743 | 0.73 | TGFBR1 (0.32) | TGFBR1KCNN3 | |
| SCHEMBL2066959 | 0.72 | DYRK1A (0.47) | TGFBR1DYRK1APDE10A | |
| SCHEMBL14432725 | 0.72 | TGFBR1 (0.35) | TGFBR1DYRK1ACYP1A2POLBCYP2D6 | |
| SCHEMBL2750457 | 0.72 | TGFBR1 (0.51) | TGFBR1DYRK1ACYP1A2NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL23290947 | 0.71 | DYRK1A (0.46) | TGFBR1DYRK1APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3159345-A1 | INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9546153-B2 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| EP-3099690-A1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-8110580-B2 | Thiophene pyrazolopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-8030304-B2 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY | 2010-09-02 | — | — | US | disclosed |
| EP-2182914-A2 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'Oreal (FR) | 2010-05-12 | — | — | EP | disclosed |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CHEN ZHAOGEN | 2010-01-28 | — | — | US | disclosed |
| EP-2076237-A1 | COMPOSITION FOR OXIDATION DYEING KERATINOUS FIBRES COMPRISING AT LEAST ONE PARTICULAR AMMONIUM SALT DERIVED FROM 18MEA, AND A COLOURING METHOD USING THE COMPOSITION | L'Oreal (FR) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009019383-A2 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'OREAL (FR) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008049767-A1 | COMPOSITION FOR OXIDATION DYEING KERATINOUS FIBRES COMPRISING AT LEAST ONE PARTICULAR AMMONIUM SALT DERIVED FROM 18MEA, AND A COLOURING METHOD USING THE COMPOSITION | L'OREAL (FR) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | CRHR1, CRH, CRHR2 | TGFBR1 1267/4885DYRK1A 2869/4885PDE10A 1053/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | TGFBR1 4565/4885DYRK1A 4868/4885PDE10A 2063/4885 |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CRH, CRHR1, CRHR2 | TGFBR1 2270/4885DYRK1A 3678/4885PDE10A 838/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | TGFBR1 4565/4885DYRK1A 4868/4885PDE10A 2063/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | TGFBR1 4565/4885DYRK1A 4868/4885PDE10A 2063/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | TGFBR1 4609/4885DYRK1A 4848/4885PDE10A 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.